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Abstract
The Clatterbridge Cancer Centre (CCC) in the United Kingdom is the world’s
first hospital proton beam therapy facility, providing treatment for ocular
cancers since 1989. A 62 MeV beam of protons is produced by a Scanditronix
cyclotron and transported through a passive delivery system. In addition to
the long history of clinical use, the facility supports a wide programme of
experimental work and as such, an accurate and reliable simulation model
of the treatment beamline is highly valuable. However, as the facility has
seen several changes to the accelerator and beamline over the years, a com-
prehensive study of the CCC beam dynamics is needed to firstly examine
the beam optics. An extensive analysis was required to overcome facility re-
lated constraints to determine fundamental beamline parameters and define
an optical lattice written with the Methodical Accelerator Design (MAD-
X) and the particle tracking Beam Delivery Simulation (BDSIM) code. An
optimised case is presented and simulated results of the optical functions,
beam distribution, losses and the transverse rms beam sizes along the beam-
line are discussed. Corresponding optical and beam information was used
in TOPAS to simulate transverse beam profiles and compared to EBT3 film
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measurements. We provide an overview of the magnetic components, beam
transport, cyclotron, beam and treatment related parameters necessary for
the development of a present day optical model of the facility. This work rep-
resents the first comprehensive study of the CCC facility to date, as a basis
to determine input beam parameters to accurately simulate and completely
characterise the beamline.
Keywords: Proton therapy, passive delivery, monte carlo, simulation,
modelling, beam optics
1. Introduction
Significant advancements in accelerator technology and growing experi-
ence with the use of ion beams for medical applications has supported the
recent emergence of charged particle therapy facilities worldwide [1]. The
benefit over conventional X-ray radiation therapy stems from the advantage
of delivering a beam with a finite range. Protons undergo interactions due
to their mass and charge, continually slowing down before they come to a
complete stop, resulting in a culmination of energy deposition: the ‘Bragg
Peak’. After this point there is negligible transfer of energy, allowing the
beam to be manipulated and delivered to targeted sites for the purposes of
treatment.
The Clatterbridge Cancer Centre is one of a few dedicated ocular proton
therapy clinics in the world [2], operating a fixed horizontal beamline which
delivers protons at 60 MeV at isocentre using a double scattering system.
This produces a conformal beam with a range of 31 mm and a sharp fall-
o↵ (0.9 mm), enabling the targeted and precise delivery of uniform dose to
tumour volumes. High rates of local tumour control, ocular retention and
preservation of visual acuity have been achieved and patients with ocular
melanoma have been successfully treated for almost 30 years [3, 4]. Since
the first set of eye patients in 1989, there are now over 70 proton therapy
facilities in operation worldwide. The majority operate at higher energies
(i.e. >160 MeV), utilising various delivery methods and arrangements of
cyclotrons, synchrotrons or synchrocyclotrons for acceleration and beamlines
and gantries for delivery [5].
Although there is a demand for higher energy beams which can treat a
greater range of cancers with conformal techniques and penetrate through



































































treatment beams [3, 6]. Uveal melanomas have the highest incidence rate
for adult ocular tumours and although treatment using other methods are
possible, proton beam therapy is considered the gold standard treatment
modality for these cases [7]. Clinical protocols have been well developed by
early facilities such as Clatterbridge; although these may vary across centres,
the ongoing experience and practised delivery of exploiting the sharpness of
the distal edge enables a large volume of patients to be treated e↵ectively.
1.1. Facility and treatment considerations
High energy, multi-room facilities require an energy selection system (ESS),
including degraders in the gantry or further upstream to decrease proton en-
ergies to levels applicable for eye treatments. This introduces additional
considerations to the transport and design of the beamline and also results
in several di↵erences to the beam quality and properties. Extensive details
can be found in literature [5, 8, 9, 10, 11] however for the context of ocular
treatments, we mention some key physical characteristics. Facilities which
operate at close to the maximum machine energy are able to generate a
fixed, passively scattered beam with minimal energy or range straggling ef-
fects. This makes it possible to produce a beam with a steep Bragg Peak
fall-o↵ whereas higher energy beams require the presence of a degrader which
also decreases transmission. Hence, consistent beam penumbrae and distal-
o↵ characteristics can be achieved regardless of the treatment prescription;
these parameters remain until the beam is modified for patient specific con-
ditions. Moreover, there is no time lost waiting on the ESS to switch between
energies and short treatment times are particularly important for the patient
experience. Quality assurance procedures are performed to maintain typical
and local treatment beam requirements. The required beam parameters for
general ocular treaments are discussed in detail in [2, 6]. A summary of these



































































Table 1: General treatment beam parameters [2].
Parameter Value
Dose rate 8-30 Gy/min
Set-up time 10-15 mins
Treatment time 30 secs
Verification precision ± 0.2 mm
Field uniformity <1%
Field diameter <34 mm
Penetration depth 4-29.3 mm
Fall-o↵ 0.9 mm (90 - 10%)
Penumbrae 1.1 mm (80 - 20%)
Modern facilities constructed by major turnkey vendors often feature the
same or related designs, systems and commissioning procedures to enable
higher consistency with day to day operation. This includes acceptance and
commissioning tests to study, verify and characterise the beam. Minimal
requirements and standards of performance must be met before initial or
regular clinical operation; these must also be maintained across the lifetime
of the equipment. As each facility or individual machine may be di↵erent,
these procedures di↵er across locations, especially those built much earlier.
The extent of characterisation and study may be limited as they are most
often unique facilities.
Consequently, there is no pre-existing optics beamline model for CCC; a
feasibility study for energy upgrades [12, 13, 14] and beam emittance and
transport work was done in the past [15, 16]. In the latter, results are in-
conclusive and there has been little attempt since to combine all findings
and understanding of the beam dynamics for practical use. Any relevant his-
torical information documented originates from the period of time prior to
and surrounding the beamline conversion, thus only pertains to it’s operation
for neutron therapy. Despite this, the beam requirements for treatment fall
within defined ranges (Table 1). In practice the operation of the accelerator
and beamline remain consistent as performance is maintained with routine
checks.
Nevertheless, it is di cult to accurately model the treatment beam with-



































































tween the delivery system and the exit of the cyclotron. As there is an
absence of functioning diagnostic systems upstream of the treatment room,
a practical approach is to examine the beam dynamics. This enables the
beam to be characterised across the entire beamline. In particular, to deter-
mine properties of the beam at the start of the treatment line as pertinent
for input parameters for simulation models.
Therefore this work is a retrospective study of sorts, to accurately model
an established proton therapy facility given the arrangement of the beamline,
components, cyclotron settings and magnetic parameters as they currently
stand. Several codes were used to develop an optical lattice of the facility
and generate a beam distribution which is compared with film measurements.
CCC has a long history of clinical treatment, supporting a wide and diverse
scope of experimental work and still remains as one of the pioneering facilities
for proton therapy. As such, this study serves as a basis for accurate simula-
tion modelling, beamline upgrades, optimisation, testing and integration of
diagnostics, with possible application for similar facilities.
2. Materials and Methods
2.1. Clatterbridge Cancer Centre
The Douglas Cyclotron and beamline was built and commissioned in 1984
initially for fast neutron therapy trials [3] before becoming a proton therapy
service. Further construction was required to accommodate a supplementary
treatment room [17] and parts of the early beamline are still contained within
the cyclotron bunker. These however are no longer in use, along with several
other components displayed in Fig. 1. The flip screens (FS), stray beam
detectors (SBD) and beam profile monitors (BPM) which are shown in the



































































Figure 1: Original layout of the complete CCC beamline. Within the vault, the cyclotron
produces the proton beam (red line) which passes through the transport line comprising
various components and magnets, to the treatment room area. Notable beamline elements;
quadrupoles (Q), dipoles (X), switching magnet (SWM) and beam collimator (BC), full
listing can be found on [18].
The Scanditronix MC-60 PF isochronous cyclotron generates a 62 MeV
beam of protons transported through nine quadrupoles arranged into three
triplets, a switching magnet and collimators before leaving the bunker and
onto the passive delivery system in the treatment room (Fig. 3a). The
treatment beamline was designed to deliver a clinically useful beam, employ-
ing a double scattering system to produce a uniform beam. Range shifting
or modulation devices can be inserted just downstream of the scatterers,
this location was found to minimise penumbra and subsequent energy losses
[3, 17, 19]. As illustrated in Fig. 3b, this includes two tungsten scattering
foils (A) with a brass stopper on the second foil, range modulator and wheel
(B & C), several collimators (E), two dose monitors (F), tungsten cross-wires
(G) and a final brass nozzle and collimator (H). Functional parameters of the
cyclotron generated proton beam are listed in Table 2.
Table 2: CCC beam parameters.
Parameter Value
Ion type p+
Nominal kinetic energy 62 MeV









































































































































Figure 3: a) The treatment room beamline; the proton beam originates from the acceler-
ator bunker behind the wall, exiting vacuum after it passes through two scattering foils
(A) and a Kapton window. b) Schematic of the delivery system and beam shaping com-
ponents. Cross-wires (G) and ionisation chambers (F) upstream of the end nozzle (H) are
used to routinely monitor the uniformity and performance of the beam.
2.2. Beamline elements
An accurate description of the beamline components is necessary and
specifically, the parameters of the magnetic elements which comprise the



































































Geometrical measurements were taken across the entire beamline (Table
3) for all relevant components in both the demarcated bunker and treatment
room areas. As the beamline is permanently fixed in place and the beam
pipe passes through a concrete wall, measurements were also checked against
original floor plans [18]. The outer diameter of all the beam pipes were not
uniform and it is unclear if this is due to changes in the thickness of the pipe
walls or if the inner dimensions also change. The minimum inner radii was
surveyed to be 30 mm and this was assumed for the simulations.
It is mentioned in [16] that the first BC after Q1 (Fig. 1) is an actuated
collimator. Presumably, it was installed to remove the beam halo or tails
[20] which skew the shape of the beam asymmetrically, causing the larger
horizontal emittance. The collimator minimises the beam spread and disper-
sion of the beam envelope specifically as it enters the switching dipole. Here
the magnetic field results in separation of particles, further horizontal beam
growth and a magnified tail downstream; BC mitigates radiation losses and
improves the beam quality for treatment.
2.3. Magnets
For the magnets, defining the physical dimensions was more problematic
as the quadrupoles were grouped into triplets with their individual yokes
and coils obscured from view (Fig. 4a). Schematics were only available
from initial neutron therapy line designs and it is not feasible to move or
disassemble any elements. Therefore, dimensions were inferred by checks
against original manufacturer drawings and the geometry for the second and
third quadrupole were extrapolated from Q1. The switching magnet (Fig.
4b) was originally used to divert the beam to other beamlines for neutron
production. The SWM has a deflection angle of 5.5  which has only slight




































































Figure 4: Close up of the second quadrupole triplet, Q2 (a) and switching magnet, SWM
(b).
Magnetic fringe fields can also be modelled in the simulation code and
this relates to the di↵erence between the physical and e↵ective lengths. For
simplicity, fringe field e↵ects were discounted by equating the total e↵ective
lengths to physical lengths, as displayed in Table 3. A lack of information and
accessibility meant that drift distances (exterior to the iron core length) be-
tween the quadrupoles were estimated. Di↵erent lengths were simulated and
smaller gaps were observed to cause blow ups in the optics further down-
stream, therefore a drift gap of 0.13 m was designated for all the triplets.
Exterior magnet dimensions were known from physical measurements, this
total length (of a triplet) accommodates multiple drift spaces and e↵ective
lengths as compensated by each quadrupole equally (Fig. 5). In the event
that more precise information is determined in the future, the optical lattice
can be matched by modifying the relevant parameters.
Figure 5: Sketch of the quadrupole triplets. Determined dimensions of the e↵ective lengths



































































2.3.1. Nominal quadrupole field gradient
It is also important to describe each quadrupole in terms of their mag-
netic strength or field gradient. This presented complications, requiring that
the limited information provided by the manufacturer and from the control
system be converted into relevant quantities. Each quadrupole triplet had
recommended operational parameters stated for each magnet and these were
scaled and optimised. As the field coverage was approximated to the e↵ec-
tive length of each quadrupole, a linear correlation was assumed to calculate
the normalised quadrupole gradients KI. This is based on the listed field
gradients and nominal current for each quadrupole, multiplied with the pro-
grammed currents. This provides an estimate of each field gradient: the
generated field gradient G = I ⇥ KI , where I is the supplied current. The
normal quadrupole strength is determined by taking this field gradient over
the beam rigidity and corresponding nominal values are also listed in Ta-
ble 3. The treatment line is indicated to begin 2.59 m downstream of Q3.
Combined with the beam transport line, the entire beamline has a length
totalling 17.92 m from the exit of the cyclotron to the treatment nozzle.
Table 3: Nominal parameters and lengths of beamline elements
Element
Physical E↵ective Normal Quadrupole
Length [m] Length [m] Strength [m
-2
]
Q11 - 0.20 -11.93
Q12 - 0.20 7.35
Q13 0.86 0.20 -6.40
Q21 - 0.22 4.14
Q22 - 0.22 1.21
Q33 0.92 0.22 -4.14
Q31 - 0.22 5.89
Q32 - 0.22 -10.92
Q33 0.92 0.22 5.89
SWM 1.13 0.85 -
Transport line 16.15 - -
Treatment line 1.77 - -




































































Two simulation codes were used to model the optical lattice, Methodical
Accelerator Design (MAD-X) [21] and Beam Delivery Simulation (BDSIM)
[22] (Section 2.4.2). In order to generate an optical lattice of the facility,
knowledge of fundamental beam properties such as the Twiss parameters
and the emittance at the source point or exit of the cyclotron, are neces-
sary to define the input beam source for simulation codes. This information
was either unknown, inconsistently documented or irretrievable. Extensive
review of documentation was necessary to locate any relevant information
from studies performed in the past [12, 15]. The more recent work in [15],
reports emittance and Twiss parameters determined by quadrupole variation
scans (QVS) at the entrance of the first quadrupole. These are listed in Table
4 and are assumed to be equivalent to the extraction point of the cyclotron.
This study encountered several uncertainties and these parameters do not
agree with historically documented measurements [12] (i.e. ✏x = 4.2, 3⇡, 2
& ✏y = 6.6, 3⇡, 1.5 mm mrad). However, it is recognised that these values
would di↵er given the changes to the cyclotron and facility over time, as
detailed in [17]. As these are the most recently reported values, they were
retained as input parameters for these beamline simulations.
Table 4: Reported Twiss parameters, dispersion and rms (1- ) emittances at the cyclotron
exit and nominal input parameters for this study [16].
Parameter Horizontal (i=x) Vertical (i=y)
Twiss Alpha (↵i) 0.8600 0.2685
Twiss Beta ( i) 1.9897 1.0629
Dispersion (Di) 0 0
Transverse Emittance (✏i) 5 mm mrad 1 mm mrad
2.4.1. Optical lattice optimisation
The CCC beamline was defined in MAD-X using the optical lattice of the
transport line combined with nominal parameters (Tables 2, 3 and 4). By
providing a description of the input beam and a sequence of magnetic ele-
ments, it is possible to obtain the Twiss functions which describe the beam
envelope throughout the beamline. The tool performs beam dynamic calcu-
lations to determine the beam ellipse at a point which can also be transported



































































at any arbitrary position which allows the flexibility to match components
and parameters to generate outputs as needed.
As mentioned in Section 2.3.1, the normal quadrupole coe cients listed
in Table 3 are approximated. Therefore a process of optimisation was nec-
essary to obtain minimal beam sizes and higher transmission. This was
performed by applying a range of factors to further scale the strengths of
each quadrupole triplet and resulting e↵ects on the optical functions, trans-
mission and calculated beam sizes along the transport line were assessed.
As these are primarily dependent on the extent and evolution of the beam
envelope, the Twiss functions were optimised to reduce erratic or large fluc-
tuations such that outputs within beamline constraints could be achieved,
these are further discussed in sections 2.5 and 2.4.2. Q1, Q2 and Q3 were
finally scaled by 0.3, 0.8, 0.8 respectively and the optimised set of simulated
Twiss functions are shown in Fig. 6.
Figure 6: Twiss functions (Twiss beta  x,  y and dispersion Dx, Dy) for the nominal case,
across the entire beamline starting from the cyclotron exit (0 m) to the nozzle (17.92 m).




































































The optical lattice was also simulated in BDSIM, to look at other aspects
of the beamline as useful for beam characterisation and for future inclusion
into a complete end-to-end model. The code utilises the Geant4 toolkit
[23, 24, 25] to simulate the beam distribution, transport, particle losses,
interactions and also has the capability of building detailed 3D geometries.
For the scope of this study and specific applicability for the facility, BDSIM
was used to visualise the beam distribution (Fig. 7), benchmark the MAD-X






Figure 7: a) CCC beamline modelled in BDSIM displaying trajectories of protons (blue)
and secondary particles (green). Beam distribution at the exit of the cyclotron in the



































































Figure 8: Comparison of Beta function plots between MAD-X (solid line) and BDSIM
(markers) in the x and y direction for 10,000 primaries.
2.5. Transverse beam size
As necessary for this study, these optimised distributions and Twiss func-
tions were further examined for the extent of their physical implications:
specifically to determine rms transverse beam sizes. The divergence and size
of the beam is essential when considering geometrical constraints of equip-
ment (i.e. beam pipe, collimators) as well as for integration of any instrumen-
tation into the beamline, either in the transport line or further downstream.











where  i is the transverse rms 1-sigma beam size and i denotes the hor-
izontal (x) or vertical (y) direction. This is determined by the Twiss beta
 i, transverse emittance ✏i, dispersion D i and the square of the relative rms
momentum spread  p/p. Furthermore, a correction was required to account













































































In this case,  Ek/Ek is the kinetic energy spread of the Scanditronix





The calculated transverse rms sigma values are plotted against distances
along the beamline and displayed in Fig. 9. To examine the reliability of the
nominal emittance (red), two other emittance values were also used to calcu-
late beam sizes as reported in [12] (blue) and by the manufacturer (green).
A diagram of the magnets has been overlaid for approximate comparison.
Figure 9: RMS beam sigma values for x (solid line) and y (dashed line) across the entire
beamline for di↵erent emittances. The nominal emittance (red line) is utilised for this
study.
2.6. Beam profile measurements
The start of the treatment line is indicated to begin at 16.15 m (Table
3). In accordance, this is also assigned as the beam source plane location for



































































with the close proximity to P1-P4, where measurements performed here may
have additional uses secondary to the beam optics, by providing a direct
determination of the beam profile. However, the closest accessible location
to non-destructively measure the beam is 38 cm downstream of this point,
where the beam exits the vacuum sealed scattering pipe (Fig. 3b) and enters
the treatment room. As such, EBT3 GafchromicTM film [26] was attached to
the downstream face of the Kapton window and irradiated to obtain relevant
information to resolve the beam profile.
The use of EBT3 film in radiation therapy is well established, typically
for machine quality assurance and as a visual check of beam characteristics.
EBT3 is also commonly used to determine beam performance and quality
in proton therapy. Its high spatial resolution and low energy dependence
enables measurements of relative dose profiles as dose maps in the transverse
plane [27]. Following exposure to radiation, the beam and dose distribution
can be obtained by evaluating the range of pixel intensities across the film as
it darkens and self develops. A close up of the Kapton window attached to
the end of the scattering tube, a xed film and obtained beam spot is shown
in Fig. 10.
(a) (b) (c)
Figure 10: a) Scattering tube protruding from the wall separating the cyclotron bunker.
The beam exits the Kapton window (orange in appearance) and enters into the treatment
room. b) Film setup. c) Beam spot on EBT3 film after irradiation and self development.
Moreover, it is noted that at the location of the film, the beam has passed
through several components (two tungsten scattering foils and a brass beam
stopper, Fig. 3b) which alter the shape and spread of the beam. This can
be seen in Fig. 10c by the distinctive void in the central area of the beam
spot, as intended by the delivery system design [19, 17]. Primarily due to the



































































such that the beam distribution will be flat and uniform at isocentre (70 mm
after the end of the treatment nozzle). As the beam here has a modified shape
and distribution, the optics calculations alone are insu cient to determine
the corresponding size of the beam. As such, particle tracking simulations are
necessary to obtain the beam distribution after it has traversed the scattering
foils and beam stopper.
Simulations were performed using a model of the delivery system [28]
developed with TOPAS (version 3.2.p1) [29], a code for proton therapy ex-
tended from the Monte Carlo simulation toolkit, Geant4. Outcomes of this
beam dynamics study contribute to e↵orts to verify and validate this and
other related models of the Clatterbridge facility [30, 31]. The input particle
source was positioned at the designated start point of the treatment beamline
and defined given known beam quantities and parameters determined from
the optical model (Tables 1, 4, 5). The simulated beam distributions after
the Kapton window are compared to those obtained with EBT3 gafchromic
film (Fig. 13).
3. Results
3.1. Optimised beam parameters
As discussed in section 2.4.1, nominal parameters were calculated for each
quadrupole and their gradients were normalised and scaled to generate an
optimised optical lattice. As the resultant physical size of the beam is the
primary consideration for our case, parameters were modified to decrease the
bounds of the optical functions and thus maximise the beam transmission.
BDSIM was used to simulate realistic beam distributions along the beamline



































































Figure 11: Particle losses across the beamline for 10,000 simulated primaries.
Further to scaling the normal quad strengths for each triplet, the resulting
beam sizes were also examined as part of the optimisation process. Fig. 12
illustrates the wide range of possible beam sizes along the transport line as
a result of changing the quadrupole parameters. Minimum or maximum  i
are denoted by either a marker or line to indicate the boundaries at either
extreme. Each marker or line type represents a set of either  x (red) or  y
(blue) values which have been generated by applying a scaling factor to the
nominal quadrupole strengths. For clarity, only the sets pertaining to the
outer boundaries have been individually displayed. The remaining series of  i
pairs are contained within the shaded region and the beam sizes determined



































































Figure 12: Ranges of possible transverse RMS beam sizes generated by varying the
quadrupole gradients. The non-solid lines and markers correspond to the sets with maxi-
mum or minimum  x (red) and  y (blue) values. All other  i sets are contained within the
shaded regions and the optimised case is indicated by the solid lines. As distances between
14.5-16.2 m are meaningful, smaller interpolation between these points are observed.
3.2. Beam sizes
Given our nominal and optimised case, the following rms beam sizes were



































































Table 5: Optimised lattice beam sizes and betatron values.
Marker Distance  x  y  x  y
Location [m] [mm] [mm] [m] [m]
Cyclotron exit 0 3.15 1.03 1.99 1.06
After SWM 6.09 15.13 3.99 45.81 15.91
End of Q3 13.56 16.95 5.43 57.48 29.47
Diagnostics P1 14.65 12.73 2.29 32.42 5.25
Diagnostics P2 14.81 12.10 1.82 29.26 3.33
Diagnostics P3 14.97 11.46 1.36 26.27 1.85
Diagnostics P4 15.14 10.83 0.91 23.44 0.82
Treatment line start 16.15 6.89 2.14 9.52 4.59
3.3. Measured and simulated profiles
The film was irradiated, calibrated and evaluated using the red channel,
given standard protocol (described in more detail in [32, 33]) to determine the
transverse beam profile at the designated point (Fig. 10b). TOPAS was used
to simulate a beam and obtain the dose deposition within defined material
equivalent to EBT3, at the same position as the film. The dose distribution
was scored in the x and y directions and plotted against position, representing
corresponding beam profiles. These were compared to the transverse profiles
obtained from film measurements and are presented in Fig. 13.
Figure 13: Transverse beam distributions in the X (left) and Y (right) direction. Film
measurements (blue) are normalised to maximum doses obtained by conversion from op-
tical density by standard protocol. Simulated profiles (red) have also been normalised to



































































In order to directly compare the two methods, plots were normalised to
corresponding maximum values. The EBT3 film provides the geometrical
beam distribution as a function of the dose, evaluated by converting the grey
value of each pixel to a net optical density (OD). The OD is dependent on
the extent of irradiation and thus each OD value results in a corresponding
dose (Gy). The dose at this location is correlated to known quantities of
radiation delivered to a (calibration) set of film irradiated at isocentre, de-
termined by ion chamber measurements. A calibration curve obtained with
this set enables conversion across the full dose range and takes into account
corrections for minor deviations in grey values and saturation e↵ects. The
film was also found to have a slight tilt in the positive x direction and an
adapted normalisation factor was applied to adjust for the non-uniformity.
Furthermore, at this location the dose is a relative value (correlated to ion
chamber further downstream) and the beam current would also be similarly
approximated. However, as the beam current is proportional to dose and
the deposition in film was directly simulated, results were also normalised to
maximum dose and plotted according to position along the axis.
4. Discussion
4.1. Beam optimisation
This work provides an extensive overview of the beam optics of the Clat-
terbridge facility, as a means to model and characterise the beam for medical
physics and research purposes. Several codes have been used to simulate the
propagation and distribution of the beam, optimising parameters and the
optical functions to assess the impact on physical beam properties in order
to generate a representative, nominal model.
Starting with our developed Twiss functions (Fig. 6), we see the increase
in dispersion in the negative direction (across the x plane) beginning around
the switching magnet but it remains constant at 0 in the y plane as the mag-
netic field generated by the dipole bends the particles in the beam only across
one plane. The switching magnet was initially responsible for diverting the
beam to the di↵erent beamlines but now just deflects the beam slightly hence
only has a small dispersive e↵ect. The betatron functions  i are dependent
on the fields produced by the quadrupoles and describe the orientation and
divergence of the beam. The beam envelopes converge following passage
through the first and second quads, however the overall changes to the opti-



































































in Fig. 9 we see the physical changes in the transverse beam sizes as largely
dependent on the optical Twiss functions. These can be observed to similarly
follow the distribution of these beta curves in Fig. 6.
We further modelled this in BDSIM, to visualise and determine the beam
size at any given point throughout the beamline. As observed in Fig. 8, the
code also models the optics functions consistent with MAD-X: both plots are
observed to agree well. Furthermore, given these simulation conditions, we
obtain a transmission of 92% from the exit of the cyclotron to the end of the
treatment line (Fig. 11). As this is an optimised case, it suggests that min-
imum beam losses of 8% are expected with this optical lattice arrangement
and assumed parameters. Large numbers of particles are lost after the SWM
as the growth in dispersion here causes an increase in the beam  x. Signifi-
cant losses occur where there is high dispersion, as seen at points of entry to
Q2 and Q3. Once the beamline and quadrupoles have been characterised, it
could be possible to improve the actual transmission e ciency. Low losses
across the transport line are ideal as once the beam enters the treatment line,
transmission dramatically reduces to a few percent. This is caused by beam
traversal through multiple components in the delivery system or gantry to
shape and correct the beam as dependent on the needs for treatment. As
purposed, the scattering system and shaping components collimate and mod-
ify the distribution to such an extent that the beam delivered for treatment
will remain consistently within specified constraints. Consequently, at this
point the uncertainties associated with this model and its representation of
the actual treatment beam and quality achieved at isocentre has a limited
and unforeseen impact. Nonetheless, what is most applicable in our study
is the determined distribution and size of the beam, as a basis for beam
parameters at the start of this treatment line.
4.2. Beam Sizes
The lattice is designed such that the beam is delivered with qualities
to fulfil its operational purpose. For operation at CCC, this mostly involves
altering the magnetic fields to transport a small and flat beam (uniform trans-
verse distribution) through the treatment nozzle. A smaller beam is desired
to maximise transmission, to avoid losses from interactions with the beam
pipe wall or parts of components which may obstruct the beam path. This
was achieved by the geometrical arrangements of quadrupoles into triplets
and by changing the quadrupole field strengths or polarities, resulting in



































































In reality, this generates a beam which should be less than the minimum
60 mm pipe diameter which can traverse the vacuum pipe at the beginning
of the treatment beamline (>16.15 m) with su cient transmission. Ideally
at this point the beam size should be small enough as the pipe contains a
first collimator of diameter 6 mm, which was considered when optimising
the lattice. At this stage the beam sigma has doubled in comparison to the
start of the transport line; additional beam sizes and corresponding betatron
values at significant locations and potential positions for diagnostics (P1-P4)
are also listed in Table 5. As these values are contingent on the reliability of
the information and parameters used in the simulation, experimental mea-
surements are necessary to benchmark this lattice. However, this cannot be
done non-destructively as the quadrupole specifications cannot physically be
checked and thus have been approximated to their best degree. As such, our
approach was to modify the normal quadrupole gradients to match actuality.
Consquently, Fig. 12 demonstrates that varying the magnet settings re-
sults in a large range of beam sizes. This is most significant at >12 m,
where knowledge of the beam parameters is most important. Therefore, ex-
perimental measurements can verify the precision of this model, which can
be benchmarked by determining the emittance or transverse beam profiles
under standard or defined accelerator settings. This is straightforward for
modern facilities which already have diagnostics devices [34, 35] installed in
their transport lines; for this case however, a system would need to be de-
signed and integrated into CCC. In terms of both the physical design and
optics, locations P1-P4 were identified as the most ideal sites for system in-
tegration for experimental measurements. These can be done using several
di↵erent methods, most suitably either; pepper pot, quadrupole variation
scans (QVS) or multiple profile measurements [36, 37, 38]. Given the nature
of the facility and beam, a combination of the latter two with a scanning
fiber system [39] is anticipated. It is aimed that measurements with this
system using multiple methods will yield Twiss parameters, emittances and
also allow simultaneous characterisation of the quadrupoles. However, as the
integration of any diagnostics devices interferes with clinical operation and
requires dissembling of the beam pipe and components, a measurement of the
transverse beam profile at the beginning of the treatment line was performed



































































4.3. Treatment line beam profiles
Comparing the film with the simulated profiles (Fig. 13), we see simi-
lar distributions however a larger penumbra is observed for both cases, with
slight deviation in the central aperture regions (5% and 2% di↵erences for x
and y, respectively). This is partly attributed to the process of conversion
from net OD, where higher uncertainties were associated with smaller dose
or net OD values. The exponential nature of the calibration curve mean that
at this lower end, marginal variations in ODs may result in augmented doses.
For the profile in x, the film exceeds the simulated dose of up to approxi-
mately 30% and 20% in y. Experimental uncertainties also contribute to
these variances as the film measurements are dependent on the beam quality
on the day. Furthermore, additional simulation studies showed that the beam
is likely to diverge more if the beam size was originally underestimated: a
smaller input beam will propagate and end up with a greater lateral spread in
comparison to a bigger input beam, at the same position. However, given the
larger emittance in x, these lower dose tails may also originate from di↵er-
ences in the scattering system geometry or additional scatter and interactions
which were not su ciently modelled.
Good agreement between the simulation and experimental profiles is ob-
served at the highest regions of dose. While testing the model with di↵erent
input beam parameters, it was also noted that the beam distribution re-
mained mostly unchanged except for the extent and elevation of the centre
dip. However, as all factors influence the beam shape, it was unclear which
parameter (beam size, angular spread etc.) had the most significant e↵ect.
The di↵erences between the two graphs are also evident of this, as the brass
stopper has the same radius and extrusion in either (x or y) direction but we
see less attenuation in y. Both the beam size and emittance are smaller in
y, indicating less spread, a slightly smaller beam width and less reduction to
the apex. The better congruence in y suggests that the optical parameters
are more realistically modelled than for x.
Given these considerations, measurements with a direct method such as
a silicon detector or beam profile monitor could provide a better indication
of the absolute distributions in the transverse plane. Varying the input emit-
tance could also result in better consistency between the plots. Nonetheless,
the agreement between these distributions suggests the applicability of the
optical study derived parameters to simulate a physically similar beam. It is
clear that at this point the beam divergence and distribution are influenced



































































tions and improvements are anticipated with further emittance and profile
measurements.
5. Conclusions
Following the change from a neutron to proton therapy service, this study
is the first comprehensive overview of the beam dynamics of the Clatter-
bridge Cancer Centre proton therapy beamline. Treatment requirements
and present day conditions of the facility and transport line provided con-
straints to define a model of the beamline simulated in both MAD-X and
BDSIM. All existing beamline information was reviewed and the quadrupole
parametrisation, simulated optical functions, rms transverse beam sizes and
transmission e ciency was investigated. The developed optical lattice can
be modified to match abitrary parameters but given discussed limitations,
an optimised case was studied. Input beam parameters derived from op-
tics calculations were used in TOPAS to generate beam profiles and these
simulated beam distributions were compared with EBT3 Gafchromic film
measurements as a baseline check. Similarities suggest the applicability of
parameters determined from the developed optical lattice where the model
can be further verified with experimental measurements.
This work aims to benefit the facility by providing a better understand-
ing of the beam produced by the cyclotron and transported through the
present arrangement of magnetic components as ultimately delivered for pa-
tient treatment. We present an extensive analysis of the linear beam optics of
the CCC transport line as necessary for upgrades, integration of instrumen-
tation and most significantly, to precisely model and completely characterise
the beamline.
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